CD8A and neoplasm: T cell depletion resulted in significantly increased tumor burden (Fig. 7G, H) and shortened survival (Fig. 7I), confirming that CD8+ T cells are essential for maintaining the long-term antitumor efficacy of CAR-M therapy.